Rare Disease Advocacy: Tamar Thompson, Global Corporate Affairs @Alexion Pharmaceuticals by AstraZeneca

01/18/25 • 24 min

95% of rare diseases do not have approved treatments, highlighting the significant unmet need in the rare disease community.
The unpredictable symptoms and long diagnostic process for conditions like neuromyelitis optica spectrum disorder (NMOSD) can lead to debilitating long-term disabilities.
There is an urgent need for increased education, resources, and support to address the global diagnostic challenge and financial burden on rare disease patients and their families.

Tamar shares her inspiring healthcare journey, starting as a provider and then transitioning to the life sciences industry after marrying an Air Force member and moving to North Dakota. She now advocates for the rare disease community, particularly focusing on NMOSD, a rare autoimmune disorder that affects the central nervous system. Tamar explains that while there are an estimated 7,000-10,000 rare diseases, only 5% have approved treatments, and 90% of these diseases do not have any approved treatments

The symptoms of NMOSD can be unpredictable and lead to long-term disabilities like vision loss and paralysis. Tamar emphasizes that the journey to diagnosis for rare disease patients can be long, often taking 7 years on average, and that NMOSD is more common in women in their mid-30s, though it can also affect men and children. Tamar discusses the challenges in diagnosing rare diseases like neuromyelitis optica spectrum disorder (NMOSD)

Rare diseases are often genetic in nature, making diagnosis difficult as symptoms can be ambiguous. Tamar highlights Alexion's history of pioneering research and development in the rare disease space, including complement-based therapies and the promise of cell and gene therapies. She emphasizes the global nature of the diagnostic challenge, with patients often seeing multiple specialists before receiving the correct diagnosis

Tamar highlights the significant financial burden on families dealing with rare diseases, with costs 10-20 times higher annually. She also touches on the promise of advancing technologies, like genome sequencing, to help with earlier diagnosis, but emphasize that access and affordability remain challenges. Overall, the discussion sheds light on the struggles faced by those impacted by rare diseases and the need for more education, resources, and support for patients and their caregivers

The discussion highlights the significant challenges faced by rare disease patients and their families, including the high financial burden and lack of awareness and support. There is a need for increased education, policy changes, and investment to foster rare disease diagnosis, treatment, and access to care.

We share the call for urgent action to address these issues and prepare for the future, given the aging population and the potential for a "silent epidemic" if left unaddressed. We discuss the challenges of diagnosing rare diseases, emphasizing the need for greater education and awareness among medical professionals.

Support the show

95% of rare diseases do not have approved treatments, highlighting the significant unmet need in the rare disease community.
The unpredictable symptoms and long diagnostic process for conditions like neuromyelitis optica spectrum disorder (NMOSD) can lead to debilitating long-term disabilities.
There is an urgent need for increased education, resources, and support to address the global diagnostic challenge and financial burden on rare disease patients and their families.

Support the show

Previous Episode

Mitochondria Unlocked: Taking Care Of Your Health at a Cellular Level, Rob Fried, CEO @Chromadex

In this episode I sit down with a good friend and mentor Rob Fried, CEO of ChromaDex, who shares his remarkable transition from Hollywood executive producer to leader of a cutting-edge nutraceutical company. Fried's journey from producing films like Rudy and Godzilla to helming a science-focused organization dedicated to extending human healthspan showcases the power of reinvention and following one's passion.
Through ChromaDex's pioneering research into NAD+ and cellular health, Fried has positioned himself at the intersection of scientific innovation and consumer wellness, bringing Hollywood storytelling skills to communicate complex scientific concepts to a broader audience.
The conversation delves deep into the crucial role of NAD+ in cellular health, particularly its impact on mitochondrial function – our cells' power plants. As Fried explains, our NAD+ levels naturally decline with age, accelerated by modern lifestyle factors like poor sleep, excessive alcohol consumption, and environmental stressors. We explore the growing need for consumer education in the supplement industry and draw compelling parallels between the responsible AI movement and the necessity for ethical governance in the supplement space. Fried advocates for establishing a responsible supplement board to ensure product quality, ingredient sourcing transparency, and consumer safety – addressing the current regulatory gaps in the industry.
Buy Here- Upgrade your cellular Health
About NAD+
NAD+ (Nicotinamide Adenine Dinucleotide) serves as a fundamental molecule in cellular health, playing multiple vital roles throughout the body. At its core, NAD+ is essential for energy production, working within our mitochondria to convert food into usable cellular energy. Beyond energy production, it acts as a crucial coenzyme for hundreds of biological processes, including DNA repair, gene expression regulation, and cellular stress response. NAD+ activates important proteins called sirtuins, which are often referred to as "longevity genes" due to their role in promoting healthy aging and cellular maintenance. As we age, our natural NAD+ levels decline, potentially contributing to various age-related conditions and decreased cellular function. This decline affects multiple aspects of health, including cognitive function, muscle strength, metabolic health, and cardiovascular wellness. Research has shown that maintaining healthy NAD+ levels can support improved energy levels, enhanced cellular repair, better brain function, stronger immune response, and more efficient metabolism. The molecule's influence extends to supporting liver health, promoting muscle recovery after exercise, regulating circadian rhythms, and potentially protecting against various age-related diseases, making it a crucial target for research in healthy aging and longevity science.
About Rob Fried
Robert Fried is the Chief Executive Officer (CEO) of ChromaDex. Mr. Fried is an Academy Award and Emmy Award-winning motion picture producer. He has held senior roles at entertainment companies Savoy Pictures (CEO), Columbia Pictures (Executive Vice President), and Fried Films (founder, CEO). He has also founded and served as CEO of internet companies Feeln (now Hallmark Movies Now), WHN (a leading e-commerce service provider), and Healthspan Research (now part of ChromaDex). Mr. Fried holds a B.S. from Cornell University and an M.B.A. from the Columbia University Graduate School of Business.

Support the show

Next Episode

The Next Frontier: Medtronic's CTO Ken Washington discusses AI, Robotics and Patient Outcomes

Medtronic's technological strategy represents a sophisticated convergence of AI, data analytics, and medical innovation, positioned to fundamentally reshape healthcare delivery. Under Chief Technology Officer Ken Washington's leadership, the organization is pioneering a model of technological augmentation that prioritizes human expertise while leveraging advanced computational capabilities. The core strategic approach focuses on developing intelligent medical devices that provide precision insights and predictive healthcare interventions.

The technology framework centers on comprehensive data infrastructure, spanning 70 distinct medical conditions. By meticulously collecting and analyzing patient data through advanced sensing technologies, Medtronic is developing AI-enabled platforms capable of personalized health monitoring and preemptive diagnostic capabilities. This approach transforms medical technology from a reactive to a predictive model, potentially reducing healthcare costs and improving patient outcomes through early intervention strategies.

Washington's innovation model extends beyond technological development to include critical considerations of regulatory compliance, global scalability, and sustainable design. With a commitment to net-zero emissions by 2045 and strategic partnerships across healthcare and technology sectors, Medtronic is positioning itself as a leader in responsible, forward-thinking medical innovation. The organization's approach integrates high-precision robotics, advanced algorithmic models, and data-driven personalization to create transformative healthcare solutions that address complex global health challenges.

About
Ken Washington serves as Senior Vice President and Chief Technology and Innovation Officer. In this role, Ken is responsible for accelerating Medtronic innovation through product development and technology strategies.

Ken joined Medtronic in 2023 and brought with him deep expertise in leading technology development and execution across industries including robotics, consumer products, automotive, and space. Ken inspires teams and pushes them even further in their ability to invent, innovate and create positive market disruptions. He partners closely with teams and leaders around Medtronic to ensure our products and therapies continue to advance the Mission to better serve patients and customers.

Prior to joining Medtronic, Ken was Vice President and General Manager of Consumer Robotics at Amazon. Prior to that, he was Chief Technology Officer at Ford Motor Company, overseeing development of the company’s technology strategy including next-generation vehicle architectures, controls and automated systems. He also spent seven years at Lockheed Martin in various leadership roles including Chief Technology Officer, Chief Privacy Officer and Vice President, Advanced Technology Center, Lockheed Martin Space Systems Company.

Ken is an internationally recognized thought leader on technology and innovation. He earned a Bachelor of Science, a Master of Science, and a PhD in nuclear engineering from Texas A&M University. He was inducted into the National Academy of Engineering in 2020 and was inducted into the Black Engineer Hall of Fame in 2023.

Support the show